Skip to main content
SpringerLink
Log in

The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The purpose of this study was to investigate the efficacy of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma Eca-109 in mice. The tumor xenograft models were established and randomly assigned to 4 groups: control group, Endostar group (1.5 mg/kg day, once daily for 3 weeks), chemotherapy group (Paclitaxel 10 mg/kg day, Cisplatin 5 mg/kg day, for 1, 7, 14, 21 days), and chemotherapy + Endostar group (combination). The length and width of tumor were measured and the tumor volumes (cm3) were calculated every other day. Three weeks later, the mice were executed, and the tumor tissues were collected to weigh and analyse the histopathology and proliferation for tumor xenograft. The results demonstrated that the tumor volumes and weight in chemotherapy + Endostar group were significantly lower than that in other three groups. Meanwhile, the cell proliferation of tumor xenograft in combined treatment group was significantly lower than that in other three groups. It was concluded that Endostar combined with chemotherapy could obviously enhance the inhibitory effect on esophageal squamous cell carcinoma Eca-109 in mice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI (2011) Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940–2007. Cancer Epidemiol Biomarkers Prev 20(1):183–186. doi:10.1158/1055-9965.EPI-10-0802

    Article  PubMed  Google Scholar 

  2. Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H (2011) Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 17(32):3745–3751. doi:10.3748/wjg.v17.i32.3745

    Article  PubMed  CAS  Google Scholar 

  3. Yang H, Sukocheva OA, Hussey DJ, Watson DI (2012) Estrogen, male dominance and esophageal adenocarcinoma: is there a link? World J Gastroenterol 18(5):393–400. doi:10.3748/wjg.v18.i5.393

    Article  PubMed  CAS  Google Scholar 

  4. Zhang L, Ge W, Hu K et al (2012) Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep 39(1):89–95. doi:10.1007/s11033-011-0713-6

    Article  PubMed  CAS  Google Scholar 

  5. Ling Y, Yang Y, Lu N, You Q (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361(1):79–84. doi:10.1016/j.bbrc.2007.06.155

    Article  PubMed  CAS  Google Scholar 

  6. Jia Y, Liu M, Huang W et al (2012) Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res 18(2):315–323. doi:10.1007/s12253-011-9447-y

    Article  PubMed  CAS  Google Scholar 

  7. Li Y, Huang XE, Yan PW, Jiang Y, Xiang J (2010) Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev 11(4):1119–1123

    PubMed  Google Scholar 

  8. Zhou N, Hu G, Mei Q, Qiu H, Long G, Chen C, Guoqing H (2011) Inhibitory effect of endostar in combination with radiotherapy in a mouse model of human CNE2 nasopharyngeal carcinoma. J Huazhong Univ Sci Technolog Med Sci 31(1):62–66. doi:10.1007/s11596-011-0151-7

    Article  PubMed  CAS  Google Scholar 

  9. Fu XH, Li J, Zou Y, Hong YR, Fu ZX, Huang JJ, Zhang SZ, Zheng S (2011) Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. Cancer Lett 312(1):109–116

    Article  PubMed  CAS  Google Scholar 

  10. Kisker O, Becker CM, Prox D et al (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61(20):7669–7674

    PubMed  CAS  Google Scholar 

  11. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59(24):6251–6256

    PubMed  CAS  Google Scholar 

  12. Zhan Q, Yue W, Hu S (2011) Effect of photodynamic therapy and endostatin on human glioma xenografts in nude mice. Photodiagnosis Photodyn Ther 8(4):314–320

    Article  PubMed  CAS  Google Scholar 

  13. Hu S, Zhang Y (2010) Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine 5:1039–1048

    Article  PubMed  CAS  Google Scholar 

  14. Sun Y, Wang J, Liu Y et al (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 23(16S):7138; Abstract presentation from the 2005 ASCO Annual Meeting

    Google Scholar 

  15. Wu H, Deng J, Yu SY, Wang X, Chen Y (2010) The Inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms. J Huazhong Univ Sci Technolog Med Sci 30(1):108–112. doi:10.1007/s11596-010-0120-6

    Article  PubMed  Google Scholar 

  16. Zhen YY, Zhao Y, Liu F, Zhang YD, Wang JJ (2010) The radiosensitization effects of endostar on human lung squamous cancer cells H-520. Cancer Cell Int 24:17–26. doi:10.1186/1475-2867-10-17

    Google Scholar 

  17. Wen QL, Meng MB, Yang B, Tu LL, Jia L, Zhou L, Xu Y, Lu Y (2009) Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 100(8):1510–1519. doi:10.1111/j.1349-7006.2009.01193.x

    Article  PubMed  CAS  Google Scholar 

  18. Peng F, Xu Z, Wang J et al (2012) Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One 7(4):e34646

    Article  PubMed  CAS  Google Scholar 

  19. Wu DS, Wu CM, Huang TH, Xie QD (2008) Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys 47(2):285–291. doi:10.1007/s00411-007-0144-x

    Article  PubMed  CAS  Google Scholar 

  20. Zhou JF, Bai CM, Wang YZ, Li XY, Cheng YJ, Chen SC (2011) Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J (Engl) 124(24):4299–4303

    CAS  Google Scholar 

  21. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y (2011) Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev 12(10):2705–2711

    PubMed  Google Scholar 

  22. Peng XC, Qiu M, Wei M et al (2012) Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemother Pharmacol 69(1):239–246. doi:10.1007/s00280-011-1695-8

    Article  PubMed  CAS  Google Scholar 

  23. Deng G, Zhao DL, Li GC, Yu H, Teng GJ (2011) Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol 34(4):824–832. doi:10.1007/s00270-011-0179-x

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the International Medical Foundation of China (CIMF-F-H001-049).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, Hebei, China

    Liang Chang, Yalei Lv, Yudong Wang, Bingjie Huo, Long Wang & Wei Liu

  2. Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China

    Fengjie Guo

Authors
  1. Liang Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fengjie Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yalei Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yudong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bingjie Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Long Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Liu.

Additional information

Liang Chang and Fengjie Guo have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, L., Guo, F., Lv, Y. et al. The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice. Mol Biol Rep 40, 669–673 (2013). https://doi.org/10.1007/s11033-012-2106-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-2106-x

Keywords

Search

Navigation